Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$98.56M

FY 2025 · Annual

Investing Cash Flow

-$90.25M

FY 2025 · Annual

Financing Cash Flow

$216.79M

FY 2025 · Annual

+144.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Depreciation & Amortization13K1.15M1.84M2M379K
Deferred Income Tax00000
Stock-Based Compensation386K1.78M3.04M12.47M12.13M
Change in Working Capital6.04M1.79M1.48M2.73M(9.52M)
Accounts Receivables00000
Inventory00000
Accounts Payables3.02M(426K)(180K)2.38M(1.56M)
Other Working Capital3.03M2.22M1.66M351K(7.95M)
Other Non-Cash Items00530K(23K)(1.6M)
Operating Cash Flow(44.18M)(54.56M)(59.5M)(81.15M)(98.56M)
Capital Expenditures(188K)(901K)(165K)(481K)(397K)
Acquisitions (Net)00000
Purchases of Investments000(93.6M)(195.4M)
Sales of Investments0000105.53M
Other Investing Activities0(229K)(50K)017K
Investing Cash Flow(188K)(901K)(165K)(94.08M)(90.25M)
Debt Repayment0(163K)3.58M(410K)(533K)
Common Stock Issued170K332K100.25M88.71M217.33M
Common Stock Repurchased000(17K)0
Dividends Paid00000
Other Financing Activities(203K)332K(35K)491K0
Financing Cash Flow150.86M189K103.79M88.78M216.8M
Effect of Forex Changes00000
Net Change in Cash106.49M(55.27M)44.13M(86.45M)27.98M
Free Cash Flow(44.37M)(55.46M)(59.66M)(81.63M)(98.96M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$100.0M
+ D&A$379.0K
+ Stock-Based Comp$12.1M
+ Deferred Tax$0
- Working Capital-$9.5M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$98.6M
- Capex-$397.0K
= Free Cash Flow-$99.0M

Analysis

FY2025 free cash flow is -$99.0M. FCF conversion is 99.0% of net income. Operating cash flow was -$98.6M, with capex of -$397.0K. The largest bridge item is Stock-Based Comp at $12.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
EFFECTEFFECT filingNov 4, 2026
S-3S-3 filingOct 29, 2026
SC 13GSC 13G filingOct 13, 2026

Does LXEO generate free cash flow?

Lexeo Therapeutics, Inc. Common Stock (LXEO) generated -$98.96M of free cash flow in fiscal 2025.

How much operating cash flow does LXEO produce?

Operating cash flow was -$98.56M, before capital expenditures of $397,000.00.